Pasithea Therapeutics Corporation has released a new investor presentation outlining the company’s current pipeline and ongoing clinical programs. The presentation provides updates on the development, manufacturing, and commercialization plans for its product candidates, including details on PAS-004 and the design and enrollment of its ongoing Phase 1 and Phase 1/b clinical trials in advanced cancer patients. Information is also provided regarding cash needs, projected cash runway, and current operating plans. The document includes data on market size and industry comparisons. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pasithea Therapeutics Corporation published the original content used to generate this news brief on January 11, 2026, and is solely responsible for the information contained therein.